Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Oldenburg, Johannes; Mahlangu, Johnny; Kim, Benjamin; Schmitt, Christophe; U. Callaghan, Michael; Young, Guy; Santagostino, Elena; Kruse‐Jarres, Rebecca; Négrier, Claude; M. Kessler, Craig; Valente, Nancy; Asikanius, Elina; G. Levy, Gallia; Windyga, Jerzy; Shima, Midori

doi:10.1056/nejmoa1703068

Public

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Published in New England Journal of Medicine • Jul 10, 2017

Authors:

Johannes Oldenburg

Johnny Mahlangu

Benjamin Kim

Abstract

BACKGROUND: Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with facto...

Subject

Medicine

Factor IX

Clinical trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!